Day R - Search Results

1

V-ATPase-associated prorenin receptor is upregulated in prostate cancer after PTEN loss.

Mohammad AH, Assadian S, Couture F, Lefebvre KJ, El-Assaad W, Barrès V, Ouellet V, Boulay PL, Yang J, Latour M, Furic L, Muller W, Sonenberg N, Mes-Masson AM, Saad F, Day R, Teodoro JG. Mohammad AH, et al. Among authors: day r. Oncotarget. 2019 Aug 13;10(48):4923-4936. doi: 10.18632/oncotarget.27075. eCollection 2019 Aug 13. Oncotarget. 2019. PMID: 31452834 Free PMC article.

2

PACE4 inhibitors and their peptidomimetic analogs block prostate cancer tumor progression through quiescence induction, increased apoptosis and impaired neovascularisation.

Levesque C, Couture F, Kwiatkowska A, Desjardins R, Guérin B, Neugebauer WA, Day R. Levesque C, et al. Among authors: day r. Oncotarget. 2015 Feb 28;6(6):3680-93. doi: 10.18632/oncotarget.2918. Oncotarget. 2015. PMID: 25682874 Free PMC article.

3

Role of proprotein convertases in prostate cancer progression.

Couture F, D'Anjou F, Desjardins R, Boudreau F, Day R. Couture F, et al. Among authors: day r. Neoplasia. 2012 Nov;14(11):1032-42. doi: 10.1593/neo.121368. Neoplasia. 2012. PMID: 23226097 Free PMC article.

4

On the cutting edge of proprotein convertase pharmacology: from molecular concepts to clinical applications.

Couture F, D'Anjou F, Day R. Couture F, et al. Among authors: day r. Biomol Concepts. 2011 Oct 1;2(5):421-438. doi: 10.1515/bmc.2011.034. Biomol Concepts. 2011. PMID: 22308173 Free PMC article.

5

Knockdown strategies for the study of proprotein convertases and proliferation in prostate cancer cells.

D'Anjou F, Couture F, Desjardins R, Day R. D'Anjou F, et al. Among authors: day r. Methods Mol Biol. 2014;1103:67-82. doi: 10.1007/978-1-62703-730-3_6. Methods Mol Biol. 2014. PMID: 24318887

6

PACE4 is an important driver of ZR-75-1 estrogen receptor-positive breast cancer proliferation and tumor progression.

Panet F, Couture F, Kwiatkowska A, Desjardins R, Guérin B, Day R. Panet F, et al. Among authors: day r. Eur J Cell Biol. 2017 Aug;96(5):469-475. doi: 10.1016/j.ejcb.2017.03.006. Epub 2017 Mar 21. Eur J Cell Biol. 2017. PMID: 28347547

7

PACE4-based molecular targeting of prostate cancer using an engineered ⁶⁴Cu-radiolabeled peptide inhibitor.

Couture F, Levesque C, Dumulon-Perreault V, Ait-Mohand S, D'Anjou F, Day R, Guérin B. Couture F, et al. Among authors: day r. Neoplasia. 2014 Aug;16(8):634-43. doi: 10.1016/j.neo.2014.07.010. Neoplasia. 2014. PMID: 25220591 Free PMC article.

8

Therapeutic uses of furin and its inhibitors: a patent review.

Couture F, Kwiatkowska A, Dory YL, Day R. Couture F, et al. Among authors: day r. Expert Opin Ther Pat. 2015 Apr;25(4):379-96. doi: 10.1517/13543776.2014.1000303. Epub 2015 Jan 7. Expert Opin Ther Pat. 2015. PMID: 25563687 Review.

9

Increasing C-Terminal Hydrophobicity Improves the Cell Permeability and Antiproliferative Activity of PACE4 Inhibitors against Prostate Cancer Cell Lines.

Dianati V, Kwiatkowska A, Couture F, Desjardins R, Dory YL, Day R. Dianati V, et al. Among authors: day r. J Med Chem. 2018 Sep 27;61(18):8457-8467. doi: 10.1021/acs.jmedchem.8b01144. Epub 2018 Sep 17. J Med Chem. 2018. PMID: 30180568

10

Multi-Leu PACE4 Inhibitor Retention within Cells Is PACE4 Dependent and a Prerequisite for Antiproliferative Activity.

Couture F, Ly K, Levesque C, Kwiatkowska A, Ait-Mohand S, Desjardins R, Guérin B, Day R. Couture F, et al. Among authors: day r. Biomed Res Int. 2015;2015:824014. doi: 10.1155/2015/824014. Epub 2015 May 31. Biomed Res Int. 2015. PMID: 26114115 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,522 results

Search Page

Filters